Gan & Lee
Gan & Lee Pharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company founded in 1998 and headquartered in Beijing, specializing in the development, production, and commercialization of recombinant insulin analogs, diabetes treatments, and medical devices. The company developed the first Chinese domestic insulin analog and markets a series of insulin products including Basalin (glargine), Prandilin (lispro), and Rapilin (aspart), along with insulin delivery devices such as GanleePen. Gan & Lee operates an industrial park of roughly 200,000 square meters and has expanded internationally, including a commercialization and supply agreement with Sandoz for biosimilar insulins in developed markets, and is advancing innovative pipeline candidates for diabetes and obesity such as GZR18, GZR4, and GZR101. The company is listed on the Shanghai Stock Exchange under stock code 603087.
Public Company
Gan & Lee is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
1998
Employees
5,000–10,000
Total Funding
$40.85M
4 rounds
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $40.85M across 4 rounds
Last updated 09-23-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Nov 12, 2014 | Pre-IPO secondary (Hillhouse, Wintersweet) | $192M | $1.6B *estimated | Hillhouse Capital |
| Oct 2012 | Pre-IPO capital increase | $30.6M | — | Not disclosed |
| Apr 2011 | Secondary — Tonghua Dongbao's 29.43% stake | $61.3M | $0.21B *estimated | Qiming Venture Partners |
Valuation Trajectory
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Entry · Series A
$73M
May 2009
Gan & Lee today
$1.6B
Nov 2014 · latest mark
Gan & Lee multiple
21.9x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Leadership
Dr. Wei Chen
Chairman & Chief Executive Officer
Dr. Gan Zhongru
Founder & Director
Qi Wang
Executive Vice President & Chief Financial Officer
Dr. John (Qiang) Wang
Senior Vice President & Chief Strategy Officer
Dr. Ting Jia
Corporate Vice President & Chief Medical Officer
Gan & Lee Investment FAQ
Gan & Lee FAQ
Gan & Lee has been a public company since 29 June 2020, when it listed on the main board of the Shanghai Stock Exchange under the code 603087 after an eight-year effort that included two withdrawn attempts. The offering sold 40.2 million shares at RMB 63.32 and raised about RMB 2.545B ($360M); the stock hit its daily limit on debut, taking the market capitalisation past RMB 36.5B. There is no further listing event pending.
Gan & Lee shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Gan & Lee raised $40.85M across 4 disclosed funding rounds prior to its public listing.
Gan & Lee was founded by Dr. Gan Zhongru in 1998.
Gan & Lee is headquartered in Beijing, China.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.